Celldex Therapeutics, Inc. (CLDX)
After hours:
| Previous close | 41.65 |
| Open | 41.07 |
| Bid | 42.16 x 100 |
| Ask | 42.27 x 100 |
| Day's range | 40.33 - 43.19 |
| 52-week range | 22.11 - 53.18 |
| Volume | |
| Avg. volume | 939,698 |
| Market cap | 2.782B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 -- Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 -- Phase 2 PN study initiated; enrollment progressing in Phase 2 EoE study -- Atopic dermatitis selected as next indication; Phase 2 study to initiate by YE 2024 - HAMPTON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeut
- GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—temperatures below skin temperatu
- GlobeNewswire
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media” section of the Celldex website. A replay will be available for 30 days following the event. About Celldex Therapeutics, Inc.Celldex i
